We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational (Refresh)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01378338
First Posted: June 22, 2011
Last Update Posted: October 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
May 24, 2011
June 22, 2011
October 1, 2013
June 2012
September 2013   (Final data collection date for primary outcome measure)
  • Rate of recurrence after treatment with PPI in patients with GERD [ Time Frame: 12month ]
  • Response rate to the treatment with PPI in patients with GERD [ Time Frame: 12month ]
Same as current
Complete list of historical versions of study NCT01378338 on ClinicalTrials.gov Archive Site
  • Baseline characteristics related to the recurrence of GERD [ Time Frame: 12month ]
  • Rate of complete resolution in each group of patients with ERD or NERD [ Time Frame: 12month ]
  • Rate of recurrence in each group of patients with ERD or NERD [ Time Frame: 12month ]
  • Quality of life measured by EQ-5D and WPAI-GERD in each group of patients with ERD or NERD [ Time Frame: 12month ]
Same as current
Not Provided
Not Provided
 
Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational
Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational Study
Recurrence rate, risk factors for the recurrence, and quality of life in patients with GERD in Korea-an observational study.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients with typical reflux symptoms (heartburn or regurgitation) undergone upper endoscopy
The Aim of This Study is to Investigate the Frequency and Related Risk Factors of Recurrence, and Quality of Life in Patients With GERD After Treatment With PPI
Not Provided
Typical reflux symptom by EGD
Total 2000 subjects who has Typical reflux symptom by EGD
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
855
September 2013
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Both ERD or NERD patient who confirmed by EGD findings within 12 months prior to V1 and have a symptom with moderate or more, at least once per week within 1 week prior to V1 and Patients between age 20 and 80with typical reflux symptoms
  • Among the patient who have not taken PPI or H2 blocker within 4 weeks prior to V1, needs to be prescribed PPIs 4~8 weeks as a part of the routine clinical practice due to typical symptom
  • Patients who give the signed informed consent

Exclusion Criteria:

  • Patients with past history of gastrointestinal surgery
  • Patients with known malignancy or history of such diseases
  • Patients with moderate to severe general medical conditions like ischemic heart disease, chronic renal failure, congestive heart failure, COPD, liver cirrhosis, acute or chronic pancreatitis, or other medical conditions which the investigator considers
Sexes Eligible for Study: All
20 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01378338
NIS-GKR-ATC-2011/1
Not Provided
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Study Director: HyeWon Koo AstraZeneca Korea
AstraZeneca
September 2013